The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.
about
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasmsDual effect of oxidative stress on leukemia cancer induction and treatmentPathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.Reduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice.Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis.Complex oncogene dependence in microRNA-125a-induced myeloproliferative neoplasms.An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.Chronic myelomonocytic leukemia: Forefront of the field in 2015.Myelodysplastic syndrome without ring sideroblasts and with Janus kinase 2 gene mutation: An unusual case reportAllogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms.Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.Routine blood examinations combined with morphological analysis for the diagnosis of myelodysplastic/myeloproliferative neoplasms.TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy.Standards and impact of hematopathology in myelodysplastic syndromes (MDS).An evolutionary perspective on chronic myelomonocytic leukemia.WHO classification of myeloproliferative neoplasms (MPN): A critical update.I walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes.Transcription factor mutations in myelodysplastic/myeloproliferative neoplasmsA case of sudden hearing loss during treatment with decitabine for chronic myelomonocytic leukemia.Importance of classical morphology in the diagnosis of myelodysplastic syndrome.Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes.A 27-Year-Old Patient Fulfilling the Diagnostic Criteria of Both CMML and JMML.An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report.Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications.Nontraumatic acute subdural hematoma associated with the myelodysplastic/myeloproliferative neoplasms.Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.JAK2 V617F mutation, multiple hematologic and non-hematologic processes: an association?Highlights of 2008 in bone marrow biopsy pathology.Laboratory diagnosis of chronic myelomonocytic leukemia and progression to acute leukemia in association with chronic lymphocytic leukemia: morphological features and immunophenotypic profile.JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia.Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols.Molecular basis of myelodysplastic/myeloproliferative neoplasms.Atypical Chronic Myeloid Leukemia in Two Pediatric Patients.New prognostic markers, determined using gene expression analyses, reveal two distinct subtypes of chronic myelomonocytic leukaemia patients.
P2860
Q24629306-21B029B7-685B-4B7E-869A-32152EFD5016Q26866544-F89970B8-4CD6-4C22-A02E-E2936EEFF5D3Q33753094-9D753A38-C35E-498F-AEFE-CE10FC47BE92Q33794297-15482142-B974-42A6-89BC-EE790674DC11Q34707445-10B7891D-961D-4CE7-9EEB-34BF5CB01792Q35264063-B23005E3-C540-434E-98BE-2BB3D53D7E8DQ36339855-E3D46D37-EF79-4E29-BAAD-3A5D2C3E7EC8Q36708989-0F9CE46F-1AE6-4FDD-8D3D-3CCE97F0B5BCQ36876853-F4A999E3-8CB8-43AD-BDC0-F47EB8217CD5Q37204110-3EFA3FDA-C432-4A12-8DCC-4C798FE5AAFEQ37205584-B38AD34D-24F1-4B6E-96F4-8D16A183AF1EQ37349392-FD515E6F-778D-42EA-AD08-E126873D124BQ37407367-96D5BBCC-6C7C-437D-969B-B2D966E342B1Q37470906-AFE561E0-EB91-45E2-8645-9280CF7D0A96Q37676277-507DF8C0-2DB9-4F81-BDB3-DB26E251B8D1Q37695094-04347BEE-14C5-464D-8DEF-CA58D49B345DQ37840934-1D89E2F7-0C91-4A1F-A7B7-D3DDCFCB88ADQ38096235-2A034E04-E67D-49B2-9207-508351E463E8Q38154519-46D8BDE2-6696-4C74-961D-82AA52E8BCB7Q38246598-A14392D6-8772-40CB-803F-6FBC388B2732Q38344558-C68071A2-7907-4AA3-BC11-848BF425E1DDQ38440190-693C0D08-E3EC-402D-B4DA-0DBF5D6B61AFQ38471249-FE2E0066-7CCA-4624-AD67-2A883A119C47Q38644826-4D0A9272-8C00-423F-B802-65FB53984E5EQ38961829-4BF187FD-B303-402D-A569-06DEBA48D703Q39048645-E979546C-6062-4091-B3DE-E625D9D059C7Q39092515-BA6C0C9F-A087-4DB7-B888-5D6F8C183F15Q40170336-8887234C-F61F-4DA3-B282-3A188294F2EAQ40184243-F892EF39-345B-4086-987C-F57B000CAFB6Q40577443-CA2238EF-A8A9-4205-813E-F3AFE99694E1Q40829877-FC3BD159-2F86-459B-B6B7-ED61FCE0599AQ41084893-1E5C81B8-5F68-423A-AD35-F6CE433CFA00Q41499758-56158EC9-134C-4306-9011-40A2810EA8F7Q41808980-D77ABC35-80B9-418B-BE17-73844B650E06Q41858668-A537C4D8-0968-41B8-8D06-8DFE3515B2FDQ41898628-75F56AFF-D035-4B8D-9398-157D9B6E2D91Q42679067-1F20AF2E-5F9B-4715-B91B-3E1B869E9EEDQ42956279-75C09205-FCFB-40A3-B402-4C7D650F3445Q43744900-0CB854E1-D1FB-44D6-A005-79575E964B6FQ43880033-C6CC0D68-59C8-475A-8C77-CC0D6F7BC9B6
P2860
The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The myelodysplastic/myeloproli ...... ases with dysplastic features.
@en
The myelodysplastic/myeloproli ...... ases with dysplastic features.
@nl
type
label
The myelodysplastic/myeloproli ...... ases with dysplastic features.
@en
The myelodysplastic/myeloproli ...... ases with dysplastic features.
@nl
prefLabel
The myelodysplastic/myeloproli ...... ases with dysplastic features.
@en
The myelodysplastic/myeloproli ...... ases with dysplastic features.
@nl
P2860
P356
P1433
P1476
The myelodysplastic/myeloproli ...... ases with dysplastic features.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2008.119
P577
2008-05-15T00:00:00Z